A Phase 4 interventional study of caspofungin in Invasive Pulmonary Aspergillosis and Chronic Obstructive Pulmonary Disease, sponsored by The First Affiliated Hospital of Guangzhou Medical University. Status unknown at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-01-23.
Sponsored by The First Affiliated Hospital of Guangzhou Medical University · Phase 4, Interventional, and Treatment
The investigators propose to study the efficacy and safety of three-week antifungal therapy with caspofungin in hospitalized patients with proven or probable IPA underlying chronic obstructive pulmonary disease.
Recently, there has been increasing appreciation of chronic obstructive pulmonary disease (COPD) as an important risk factor of invasive pulmoanry aspergillosis (IPA). However, clinical data on the morbidity and mortality of IPA underlying COPD as well as the efficacy and safety of antifungal treatment in such subset of patient population is very limited. In clinical pratice, capofungin is often used as primary antifungal therapy for IPA, especially in patients with impaired renal function. Based on this data, the investigators propose to study the efficacy and safety of three-week antifungal therapy with caspofungin in hospitalized patients with proven or probable IPA underlying COPD.
48 studies on the registry are indexed under Invasive Pulmonary Aspergillosis; 9 are open to participants now.
This study's planned enrollment of 40 is below the median of 85 across 13 interventional studies indexed under Invasive Pulmonary Aspergillosis.
Browse Invasive Pulmonary Aspergillosis studies →The First Affiliated Hospital of Guangzhou Medical University is the lead sponsor of 165 studies on the registry; 67 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: caspofungin
Caspofungin injection, intravenously administered, loading dose at 70mg qd for the first 24hrs, maintenance dose at 50mg qd for the following 20 days
Also known as: brand name:Cancidas
Global response (defined as both clinical and microbiologic success) at the end of intravenous therapy
The primary objective is to investigate the clinical efficacy of 3-week treatment with caspofungin as either primary or salvage antifungal therapy for IPA underlying COPD.
Time frame: At end of intravenous treatment(three week)
Assessment of Safety of Caspofungin for IPA Underlying COPD
Safety evaluation : Laboratory examinations are performed; Number of participants with adverse events are recorded.
Time frame: at the time of enrollment, weekly during therapy, and 1 week after the end of therapy.
Global response to 2-week caspofungin therapy
Time frame: 2 week
Factors such as severity of COPD, exposure to systemic corticosteroids,extended-spectrum antibiotics et al. affecting patients' response to caspofungin therapy
Assessment of factors such as severity of COPD, exposure to systemic corticosteroids,extended-spectrum antibiotics,malnutrition or diabetes affecting patients' response to caspofungin therapy
Time frame: 3 week
Clinical response at Day 7 of treatment
Time frame: 1 week
This study is status unknown, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Caspofungin
Invasive Pulmonary Aspergillosis →
The First Affiliated Hospital of Guangzhou Medical University →